Log in

NASDAQ:PETQPetIQ Stock Price, Forecast & News

$33.67
-1.27 (-3.63 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$33.58
Now: $33.67
$35.58
50-Day Range
$28.82
MA: $32.23
$35.83
52-Week Range
$15.83
Now: $33.67
$36.50
Volume221,800 shs
Average Volume385,616 shs
Market Capitalization$955.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
PetIQ, Inc. operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers Rx pet medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; and OTC medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars. It also provides health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company offers its products primarily under the PetIQ, PetAction Plus, Advecta, PetLock Plus, and TruProfen brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 39 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It sells its products through approximately 60,000 points of distribution across retail and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Read More
PetIQ logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Drugs, proprietaries, & sundries
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PETQ
CUSIPN/A
Phone208-939-8900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$709.43 million
Cash Flow$1.39 per share
Book Value$11.60 per share

Profitability

Net Income$-11,450,000.00

Miscellaneous

Employees1,866
Market Cap$955.55 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive PETQ News and Ratings via Email

Sign-up to receive the latest news and ratings for PETQ and its competitors with MarketBeat's FREE daily newsletter.

PetIQ (NASDAQ:PETQ) Frequently Asked Questions

How has PetIQ's stock been impacted by COVID-19 (Coronavirus)?

PetIQ's stock was trading at $22.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PETQ stock has increased by 49.0% and is now trading at $33.67. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PetIQ?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PetIQ.

When is PetIQ's next earnings date?

PetIQ is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for PetIQ.

How were PetIQ's earnings last quarter?

PetIQ Inc (NASDAQ:PETQ) announced its quarterly earnings results on Thursday, May, 7th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.02. The firm had revenue of $186.78 million for the quarter, compared to analyst estimates of $176.52 million. PetIQ had a negative net margin of 2.03% and a positive return on equity of 8.28%. View PetIQ's earnings history.

What price target have analysts set for PETQ?

4 analysts have issued twelve-month price objectives for PetIQ's shares. Their forecasts range from $35.00 to $44.00. On average, they anticipate PetIQ's share price to reach $40.00 in the next year. This suggests a possible upside of 18.8% from the stock's current price. View analysts' price targets for PetIQ.

Has PetIQ been receiving favorable news coverage?

News coverage about PETQ stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PetIQ earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about PetIQ.

Who are some of PetIQ's key competitors?

What other stocks do shareholders of PetIQ own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetIQ investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Intel (INTC), Advanced Micro Devices (AMD), CVS Health (CVS), Exelixis (EXEL), salesforce.com (CRM), Crispr Therapeutics (CRSP) and IBM (IBM).

Who are PetIQ's key executives?

PetIQ's management team includes the following people:
  • Mr. McCord Christensen, Chairman & CEO (Age 47)
  • Ms. Susan Sholtis, Pres (Age 53)
  • Mr. John Newland, Chief Financial Officer (Age 55)
  • Mr. Robert Michael Herrman, Gen. Counsel & Sec.
  • Mr. Adam Fellers, Sr. VP of Sales

When did PetIQ IPO?

(PETQ) raised $86 million in an IPO on Friday, July 21st 2017. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies and William Blair served as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.

What is PetIQ's stock symbol?

PetIQ trades on the NASDAQ under the ticker symbol "PETQ."

Who are PetIQ's major shareholders?

PetIQ's stock is owned by many different institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (2.36%), Envestnet Asset Management Inc. (0.11%) and Xcel Wealth Management LLC (0.02%). Company insiders that own PetIQ stock include Ecp Helios Partners Iv, LP, James Nathan Clarke, John Newland, Mccord Christensen, Robert Michael Herrman, Susan Sholtis and Will Santana. View institutional ownership trends for PetIQ.

Which institutional investors are buying PetIQ stock?

PETQ stock was acquired by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Envestnet Asset Management Inc., and Xcel Wealth Management LLC. Company insiders that have bought PetIQ stock in the last two years include James Nathan Clarke, John Newland, and Robert Michael Herrman. View insider buying and selling activity for PetIQ.

How do I buy shares of PetIQ?

Shares of PETQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PetIQ's stock price today?

One share of PETQ stock can currently be purchased for approximately $33.67.

How big of a company is PetIQ?

PetIQ has a market capitalization of $955.55 million and generates $709.43 million in revenue each year. The company earns $-11,450,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. PetIQ employs 1,866 workers across the globe.

What is PetIQ's official website?

The official website for PetIQ is www.petiq.com.

How can I contact PetIQ?

PetIQ's mailing address is 923 S. Bridgeway Pl., EAGLE ID, 83616. The company can be reached via phone at 208-939-8900 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.